TrialClinical breast cancer2019

Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.

Lynn Symonds et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.